Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


  • Mirimus Inc has collaborated with Biogen Inc (NASDAQ:BIIB) to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications. 
  • Terms of the collaboration are not disclosed.
  • Under the agreement, Mirimus will engineer RNAi-based therapeutics that Biogen will assess to determine feasibility in potential neurological disease settings. 
  • If feasibility is established, the companies will have the option to pursue pre-clinical development of the asset(s).
  • Price Action: BIIB shares are down 0.75% at $320.06 during the market session on the last check Wednesday.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsHealth CareContractsGeneralBriefs